SPRC SciSparc
- 0.3670
- -0.0114-3.01%
- 0.4600
- +0.0930+25.34%
SciSparc News
Express News | SciSparc Shares Are Trading Higher After the Company Submitted an Investigational New Drug (IND) Application to the FDA for SCI-110
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients With Tourette Syndrome
Express News | Scisparc Submitted Ind Application to the FDA for Sci-110 Phase Iib Clinical Trial for Patients With Tourette Syndrome
SciSparc Ltd. Calls for Crucial Shareholder Votes
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to Its Scientific Advisory Board
Express News | Scisparc: Mitocarex Appointed Professor Nir Peled, Seasoned Oncologist, to Its Scientific Advisory Board
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
SciSparc Initiates Groundbreaking Autism Therapy Trial
Express News | SciSparc Enrolls First Five Patients In Clinical Trial Ot Its SCI-210 Treatment
Express News | Scisparc Announces Enrollment of the First Five Patients in the Clinical Trial of Its Innovative Sci-210 Treatment
Wall Street Set to Open Slightly Higher Monday After Strongest Week of 2024
US Markets Flat in Pre-Bell Following Biggest Weekly Gain of 2024
Express News | SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain
SciSparc Ltd. Grants Exclusive License to Polyrizon
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
Top Premarket Gainers
SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)
Trending Stocks Today | SciSparc Surges 43.91% Post-Market
SciSparc Licenses SCI-160 Pain Drug Program to Polyrizon
SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
Analysis
Price Target
No Data
